The Archive · 3 posts
Discover Immupharma's innovative drug development on the LSE! 💊 IMM is pioneering solutions for autoimmune diseases with cutting-edge science. 🔬✨
ImmuPharma's 2025 results: cash improves to £1.4m, £6.5m post-period raise, P140 partnership talks continue, Kapiglucagon accelerated. Still loss-making, but better funded into 2027.
May 27, 2026
Showing 2 of 3 posts
ImmuPharma reports £1.8m interim loss amid major P140 breakthroughs (non-immunosuppressive mechanism proven) and active global partner talks.
JoshuaAugust 6, 2025
ImmuPharma's 2024: P140 autoimmune therapy advances with unique mechanism, narrowed losses & strategic funding. Biotech insights here.
JoshuaMay 19, 2025